Mar 26 |
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
|
Mar 26 |
Mesoblast gains as FDA backs regulatory plans for cell therapy
|
Mar 26 |
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|
Mar 13 |
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
|
Mar 11 |
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
|
Mar 11 |
Biggest stock movers today: Crypto-linked stocks, MESO and more
|
Mar 10 |
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
|
Feb 29 |
Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript
|
Feb 29 |
Mesoblast Limited 2024 Q2 - Results - Earnings Call Presentation
|
Feb 29 |
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
|